Boosting the production of price controlled medicines

1821. SHRI EKANATH K. THAKUR: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether Government are aware of the fact that over the last one decade, about a fifth of all medicines, which Government have kept under price control, have either smartly escaped the control norms or have been abandoned by companies in favour of imports;

(b) whether it is a fact that the number of companies selling price controlled medicines such as anti-psychotic drug Chloropropamide and Riboflavin (Vitamin B1) have come down significantly; and

(c) if so, the steps Government propose to take to boost the production of price controlled medicines?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI B.K. HANDIQUE): (a) to (c) The 74 bulk drugs specified in the First Schedule of the Drugs (Prices Control) Order, 1995 (DPCO, 95) and the formulations based thereon are under price control and their prices are fixed/revised by the National Pharmaceutical Pricing Authority (NPPA) in accordance with the provisions of DPCO, 95. These drugs have been kept under price control on the basis of criteria mentioned in 'Modifications in Drug Policy, 1986', announced in September 1994.

The National Pharmaceutical Pricing Authority (NPPA) has no specific information regarding the fact that over the last one decade, about a fifth of all medicines, which Government have kept under price control, have either smartly escaped the control norms or have been abandoned by companies in favour of imports and the number of companies selling price controlled medicines such as antipsycotic drug Chloropropamide and Riboflavin (Vitamin B2) have come down significantly.

However no specific case of shortage of these drugs recently has been brought to the notice of NPPA.

Drug Price Equalization Accounts

1822. SHRI UDAY PRATAP SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the total number of drugs for which Drug Price Equalization Accounts provision exists;

(b) what are the names of drugs and the companies where DPEA liability has been calculated; and

(c) the name of the companies and drugs for which the notice of recovery under DPEA have been sent?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI B.K. HANDIQUE): (a) As per para 17(1) of the Drugs (Prices Control) Order, 1979 (DPCO 1979); the Government shall maintain an account to be known as the Drugs Prices Equalisation Account to which shall be credited;

(a) by the manufacturer, the importer or distributor, as the case may be—

(i) the amount determined under sub-paragraph (2) of Paragraph 7; (*i.e.* where a manufacturer of formulations utilizes in his formulations any bulk drug, either from his own production or procured by him from any other source, the price of such bulk durg being lower than the price allowed to him in the price of his formulations, the Government may require such manufacturer to deposit into the Drug Prices Equilisation Account; the excess amount to be determined by the Government)

(ii) the excess of the common selling price or, as the case may be, pooled price over his retention price.

The DPEA liability of a drug company is determined as per above provisions of DPCO 1979. The Drug Prices Liability Review Committee (DPLRC)/Department on the recommendation of DPLRC have computed the liability in respect of 45 companies covering 22 bulk drugs. The total number of bulk drugs for which Drug Price Equalisation Account liability exists could be known when the DPEA liability in all cases under DPCO 1979 is computed after the vacation of the interim stay dated 30.6.1997 granted by the Hon'ble Bombay High Court in Writ Petition No. 2368/1996 filed by Indian Drug Manufacturers' Association (IDMA) and Organisation of Pharmaceutical Producers of India (OPP) restraining the Department and its committees etc. from issuing fresh notices to the drug companies calling for information required for determining liabilities.

(b) A statement containing the name of the companies and drugs where DPEA liability has been computed by the Department on the basis of the recommendations of DPLRC and also quantified by the Committee is attached as Statement—I (*See* below)

(c) A statement containing the name of the companies and drugs for which the notice of recovery for DPEA liability under the provisions of DPCO 1979 has been sent is attached as Statement—II.

Statement-I

Name of the companies and drugs where the amount of liability has been computed by the Department on the basis of recommendations of the DPLRC/quantified by the DPLRC

Sl.No.	Name of the company	Name of the bulk drug
1	M/s Anil Starch Products Ltd.	Dextrose Anhydrous
2	M/s Franco Indian Pharma & M/s Griffon Labs	Phenoxymethyl Penicillin formulations (Peniviral Tabs)
3	M/s Parke Davis (I) Ltd.	Isokin Tab & Liquid
4	M/s Wallace Pharma Ltd.	Rifampicin
5	M/s Astra IDL Ltd.	Rifampicin
6	M/s Wyeth Lederle	Dexamethasone
7	M/s Biddle Sawyers Ltd.	Salbutamol Sulphate
8	M/s PCI Ltd.	Rifampicin
9	M/s PCI Ltd.	Amoxycillin Trihydrate
10	M/s Bayer (India) Ltd	Chloroquin Phosphate
11	M/s PCI Ltd.	Gentamycin Sulphate
12	M/s Yash Pharma Labs	Ethambutol
13	M/s PCI Ltd.	Ethambutol
14	M/s PCI Ltd.	Ampicillin Trihydrate
15	M/s Pharmed Ltd.	Rifampicin
16	M/s Alembic Chemical Works	Rifampicin
17	M/s Merind Ltd.	Dexamethasone
18	M/s Biochem Pharma Industries	Rifampicin
19	M/s Lupin Laboratories	Rifampicin
20	M/s Unique Pharmaceuticals	Oxyphenabutazone
21	M/s Ambalal Sarabhai Enterpises	Amoxycillin Trihydrate
22	M/s Gufic Ltd.	Amoxycillin Trihydrate
23	M/s Lyka Labs	Ampicillin Trihydrate
24	M/s Unique Pharma Labs. Ltd.	Metronidazole

Sl.No.	Name of the company	Name of the bulk drug
25	M/s Ranbaxy Laboratories Ltd.	Ampicillin Trihydrate
26	M/sLyka Labs.	Rifampicin
27	M/s Lyka Labs. Ltd.	Ethambutol
28	M/s Dolphin Labs. Ltd.	Amoxycillin Trihydrate
29	M/s Astra-IDL Ltd.	Ibuprofen
30	M/s Ranbaxy Lab.s Ltd.	Rifampicin
31	M/s Themis Chemicals	Refampicin
32	M/s Cipla Ltd.	Metronidazole
33	M/s Lyka Labs. Ltd.	Amoxycillin Trihydrate
34	M/s Knoll Pharmaceutical	Ibuprofen
35	M/s Themis Chemicals	Ethamubtol
36	M/s Lyka Labs	Fluocinolone Acetonide
37	M/s Dolphin Labs. Ltd.	Metronidazole
38	M/s Tamil Nadu Dadha	Calcium Lactate
39	M/s Boehringer Mannheim (India) Ltd.	Euglucon Tabs
40	M/s U.S. Vitamins Ltd.	Doxycycline
41	M/s Dolphin Labs Ltd.	Sulphamethaxazole & Trimethoprim
42	M/s Cyanamid (India) (Now M/s Wyeth Ltd.)	Dimethyl Chloro-Tetracycline Hydrochloride etc.
43	M/s S.G. Pharmaceuticals (M/s Ambalal Sarabhai Enterprises Ltd.)	Oxyphenbutazone
44	M/s John Wyeth and Geoffrey Manners (now Wyeth Ltd.)	Benzathine Pencillin G
45	M/s Ethico Drugs & Chemicals Mfg. Co. Ltd.	Rifampicin

Statement-II

The names of companies and drugs for which the notice of recovery under DPEA has been sent

Sl.No.	Name of the company	Name of the bulk drug
1	M/s Anil Starch Products Ltd.	Dextrose Anhydrous
2	M/s Franco Indian Pharma & M/s Griffon Labs	Phenoxymethyl Penicillin formulations (Penivoral Tabs)
3	M/s Parke Davis (I) Ltd.	Isokin Tab & Liquid
4	M/s Wallace Pharma Ltd.	Rifampicin
5	M/s Astra IDL Ltd.	Rifampicin
6	M/s Wyeth Lederle	Dexamethasone
7	M/s Biddle Sawyers Ltd.	Salbutamol Sulphate
8	M/s PCI Ltd.	Rifampicin
9	M/s PCI Ltd.	Amoxycillin Trihydrate
10	M/s Bayer (India) Ltd.	Chloroquin Phosphate
11	M/s PCI Ltd.	Gentamycin Sulphate
12	M/s Yash Pharma Labs	Ethambutol
13	M/s PCI Ltd.	Ethambutol
14	M/s PCI Ltd.	Ampicillion Trihydrate
15	M/s Pharmed Ltd.	Rifampicin
16	M/s Alembic Chemical Works	Rifampicin
17	M/s Merind Ltd.	Dexamethasone
18	M/s Biochem Pharma Industries	Rifampicin
19	M/s Lupin Laboratories	Rifampicin
20	M/s Unique Pharmaceuticals	Oxyphenabutazone
21	M/s Ambalal Sarabhai Enterprises	Amoxycillin Trihydrate
22	M/s Gufic Ltd.	Amoxycillin Trihydrate
23	M/s Lyka Labs	Ampicillin Trihydrate
24	M/s Unique Pharma Labs Ltd.	Metronidazole
25	M/s Ranbaxy Laboratories Ltd.	Ampicillin Trihydrate

Sl.No.	Name of the company	Name of the bulk drug
26	M/s Lyka Labs	Rifampicin
27	M/s Lyka Labs Ltd .	Ethambutol
28	M/s Dolphin Labs Ltd.	Amoxycillin Trihydrate
29	M/s Astra - IDL Ltd.	Ibuprofen
30	M/s Ranbaxy Labs Ltd.	Rifampicin
31	M/s Themis Chemicals	Rifampicin
32	M/s Cipla Ltd.	Metronidazole
33	M/s Lyka Labs Ltd.	Amoxycillin Trihydrate
34	M/s Knoll Pharmaceutical	Ibuprofen
35	M/s Themis Chemicals	Ethambutol
36	M/s Lyka Labs	Fluocinolone Acetonide
37	M/s Dolphin Labs Ltd.	Metronidazole
38	M/s Tamil Nadu Dadha	Calcium Lactate
39	M/s Boehringer Mannheim (India) Ltd.	Euglucon Tabs
40	M/s U.S. Vitamins Ltd.	Doxycycline
41	M/s Dolphin Labs Ltd.	Sulphamethaxazole & Trimethoprim
42	M/s S.G. Pharmaceuticals (M/s Ambalal Sarabhai Enterprises Ltd.)	Oxyphenbutazone
43	M/s Ethico Drugs & Chemicals Mfg. Co. Ltd.	Rifampicin

Settlement Commission on DPEA cases

1823. SHRI UDAY PRATAP SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) what are the details of DPEA liabilities which are due from the MNCs and the Indian companies;

(b) what are the names of the companies, names of the drugs and the amount involved;